Seasonic’s New High Efficiency 1.6 kW Platform for Broad Power Supply Portfolio Use Built With Transphorm GaN
Transphorm Inc.— the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified gallium nitride (GaN) semiconductors—today announced that Seasonic Electronics Co. uses Transphorm’s high voltage (HV) GaN FETs in its new 1600 Watt (W) bridgeless totem-pole power factor correction (PFC) platform: the 1600T. The 1600T is the power supply manufacturer’s highest performing PFC platform to date at greater than 99 percent efficiency. Notably, the introduction of GaN delivers a two percent efficiency increase and 20 percent power density increase over Seasonic’s previous Silicon-based platform.
The 1600T platform will be scaled and deployed in various catalog products targeting the Charger (e-scooters, industrial, etc.), Gaming, Server, and PC power markets.
“When researching semiconductor technologies that would enable us to reach world-leading efficiency levels, gallium nitride stood out as an attractive alternative to Silicon,” said Paul Lin, Director of Research and Development, Seasonic. “We knew the bridgeless totem-pole PFC was the topology we would use in our first high voltage GaN power platform. So, we needed power semiconductors capable of successfully capitalizing on that topology. What’s more, we wanted a GaN solution that could be backed by our standard warranty. We ultimately opted for Transphorm’s FETs within the 1600T given their proven performance and reliability that allowed us to meet those requirements.”
Designing with Confidence: Transphorm Q+R
The 1600T platform employs Transphorm’s TP65H035WS device, a 650 V GaN FET with an RDS(on) of 35 mΩ in a standard TO-247 package. The transistor achieves increased efficiency in hard-and soft-switched circuits, providing power systems engineers options when designing products. Further, the TP65H035WS pairs with commonly-used gate drivers to simplify designs while controlling costs.
Transphorm prioritizes quality and reliability (Q+R) when developing its GaN platforms and FETs. An outcrop of that prioritization is increased safety for designers; Transphorm GaN typically delivers greater headroom and noise immunity when compared to other available GaN FETs. The TP65H035WS’ typical gate threshold is 4 V with a maximum gate voltage of ±20 V.
Beyond the technology itself, Transphorm offers in-depth field application support and hands on training given GaN’s relative newness in high voltage applications. Seasonic leveraged the semiconductor company’s experts to strengthen the design itself while quickening time to market.
For example, guidance provided helped Seasonic’s team ramp on use of a simple, low-cost digital signal processor (DSP) to control the totem-pole PFC. Transphorm also aided in the platform’s component selection and system layout, ensuring optimal GaN performance. Ultimately, the co-development directly impacted Seasonic’s ability to drive up thermal efficiency while increasing power output—generating a HV GaN platform capable of delivering on Seasonic’s vision.
About Seasonic Electronics
Seasonic is a truly global company. Headquartered in Taipei, Taiwan, we export our products from our factory in China to our offices in the USA, Europe, Japan, as well as to other parts of the world. As a leader in innovation, our company’s main focus is to bring the latest technology at the best possible value to all our customers, who require cutting-edge features combined with market leading performance and total reliability. The strong competition in the IT industry gives us constant challenges, which strengthen our resolve to become and stay the best. Today, the Seasonic name is the equivalent of high performance, excellence and reliability. Our design and engineering team is passionate about creating new solutions that reply to the needs of our customers and connect to the latest market trends.
Transphorm (transphormusa.com) designs, manufactures, and sells the highest performance, highest reliability GaN semiconductors for high-voltage power conversion applications. Holding one of the largest Power GaN IP portfolios (1000+ issued and pending patents worldwide), Transphorm produces the industry’s only JEDEC and AEC-Q101 qualified GaN FETs. This is due to a vertically-integrated business approach, which allows for innovation at every stage: materials and device design and manufacture, fabrication, packaging, reference circuit designs, and application support.
Heather Ailara, 845-424-6341
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu